US Pharma MarketingFDA quietly stops releasing CRLs
FDA paused public release of pharma rejection letters (CRLs) after a law firm Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA:…
The FDA has paused its public release of pharma rejection letters as the agency seeks to avoid litigation around releasing the often sensitive information.
The pause follows a law firm in April
Source: Endpoints News